Comment on FR Doc # 2012-11586

It is the opinion of Gamma Therapeutics, an early stage biotechnology venture, that the following elements of the new rules be strongly considered for final review and passing: (1) 100% versus currently 50% of the small business should be owned by a United State company; (2) A small business be further defined, as regards the award of SBIR or STTR monies, in categories that define its position in the market, i.e., discovery, early stage, small business, growth, for the purposes of prioritizing awarding of monies; (3) That a small business be further defined as under 50 employees and $50 M in revenue versus the 100 employees and $500 M in revenues; (4) That priority of awards be given to innovative start-up developing new and promising technologies, first, versus small businesses already making revenue from products; (5) That the proposal award period be reduced from the current 6 months to 3 months, in order to provide grant monies faster to requesting companies; and; (6) That the paperwork be vastly reduced so that no grant documentation is greater than 25 pages versus the 50 plus pages seen today; (7) That business people in the industry of the SBIR/STTR grant requestor be part of the review committee for commericalization funds who bring business and industry experience to the table and understand the necessity of the grant monies from the standpoint of product development, cost of development and general finances.